Moderna (MRNA) Cash from Operations (2018 - 2026)

Moderna (MRNA) has reported Cash from Operations for 9 consecutive years, with -$526.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Operations rose 42.76% year-over-year to -$526.0 million in Q2 2026; TTM through Jun 2026 was -$1.1 billion, a 60.22% increase from a year earlier, with the FY2025 full-year figure at -$1.9 billion, up 37.65% from the prior year.
• Cash from Operations was -$526.0 million for Q2 2026 at Moderna, up from -$630.0 million in the prior quarter.
• Over five years, Cash from Operations peaked at $2.8 billion in Q1 2022 and troughed at -$1.6 billion in Q3 2023.
• A 5-year average of -$231.7 million and a median of -$738.5 million in 2025 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations sank 734.92% in 2023 and jumped 45.91% in 2025, its largest moves.
• Over 5 years, Cash from Operations stood at $1.7 billion in 2022, then sank by 62.58% to $622.0 million in 2023, then surged by 32.64% to $825.0 million in 2024, then increased by 12.73% to $930.0 million in 2025, then plunged by 156.56% to -$526.0 million in 2026.
• The last three Cash from Operations figures came in at -$526.0 million (Q2 2026), -$630.0 million (Q1 2026), and $930.0 million (Q4 2025), per Business Quant data.